UPDATE: Rodman & Renshaw Reiterates Market Outperform on AVI BioPharma, Reduces PT to $2

Rodman & Renshaw reiterated its Market Outperform rating on AVI BioPharma (NASDAQ: AVII). At the same time, the rating agency reduced its price target on the company's stock from $4 to $2. On Monday, AVII closed the day at $1.15.